Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Low Risk

Score: 25/100

Failure Rate

0.0%

0 terminated/withdrawn out of 6 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

33%

2 trials in Phase 3/4

Results Transparency

0%

0 of 2 completed trials have results

Key Signals

Enrollment Performance

Analytics

Phase 3
1(33.3%)
Phase 4
1(33.3%)
N/A
1(33.3%)
3Total
Phase 3(1)
Phase 4(1)
N/A(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (6)

Showing 6 of 6 trials
NCT04848493Completed

National Project on Vaccines, COVID-19 and Frail Patients

Role: collaborator

NCT05947903Not Yet Recruiting

Validation of the European Oncology Quality of Life Toolkit

Role: collaborator

NCT05906277Not ApplicableUnknown

Biobanking and New Biomolecular Metrics

Role: collaborator

NCT05746858Not Yet Recruiting

Predictive Biomarkers Including miRNA-based Tumor Signatures in Diffuse Large B Cell Lymphoma (R/R DLBCL) (MIMOSA)

Role: collaborator

NCT00525395Phase 3Unknown

Virus Early Transcription Factor (VETF) Multicenter Phototherapy Protocol

Role: lead

NCT00723437Phase 4Completed

Evaluation of the Efficacy of Acitretin Therapy for Nail Psoriasis

Role: lead

All 6 trials loaded